COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
PDDS 2022 Speakers
Alena Korbut
IHS/Cherokee Nation, United States
Victoria Demina
NEUWAY Pharma GmbH, Germany
Samir Haddouchi
Sotax Pharma Services, France
Miroslav Radenkovic
University of Belgrade, Serbia
Mirjana B. Colovic
University of Belgrade, Serbia
Madhav Bhatia
University of Otago, New ZealandSubmit your abstract Today
Title : Drug Delivery to the Brain using Engineered Protein Capsules (EnPCs®)
Victoria Demina, NEUWAY Pharma GmbH, Germany
Title : Mucoadhesive systems for the fast delivery of drugs
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Hydrogen Sulfide: A Stinky Gas….. and Novel Therapeutic Target for Inflammatory Disease
Madhav Bhatia, University of Otago, New Zealand
Title : Arsenate target specific cell death mechanism in normal and tumoral breast cancer cell lines
Cornelia Braicu, Iuliu Hațieganu University of Medicine and Pharmacy, Romania
Title : Vaccines against rotavirus, data based on a study for safety and efficacy
Merita Kucuku, Freelance consultant, Albania
Title : Cardiac myosin inhibitors – New pharmacological approach for obstructive hypertrophic cardiomyopathy treatment
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Self microemulsifying systems based topical lipstick of antifungal agent
Bhupendra Gopalbhai Prajapati, Ganpat University, India
Title : Development and Evaluation of Structured Strategic Approach for successful accomplishment of Risk-Based Monitoring model from clinical trial inception to completion at clinical trial organization.
Heema Desai, Texila American University, India
Title : Immune checkpoint inhibitors (ICIs) and immune-related adverse drug reactions: Focus on their neurotoxicity
Liberata Sportiello, University of Campania “L. Vanvitelli”, Italy
Title : Latest trends in Bio-degradation of Xenobiotics for cleaning up the environment
Neha Agarwal, University of Lucknow, India